Cover Image
Market Research Report
Product code 
1040006

Global Central Nervous System (CNS) Biomarkers Market - 2021-2028

Published: | DataM Intelligence | 180 Pages | Delivery time: 2 business days

Price

Back to Top
Global Central Nervous System (CNS) Biomarkers Market - 2021-2028
Published: December 1, 2021
DataM Intelligence
Content info: 180 Pages
Delivery time: 2 business days
  • Description
  • Table of Contents

Market Overview

Biomarkers are measurable biological indicators that help understand the development of chronic diseases, their relationship with environmental chemicals and identify subjects at high risk of developing the disease.

The global central nervous system (CNS) biomarkers market size was valued US$ XX million in 2020 and is estimated to reach US$ XX million by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Market Dynamics

The development of novel biomarkers for diagnosing and treating Alzheimer's disease is expected to drive market growth.

Increased life expectancy has resulted in an older population, which has increased dementia prevalence. Alzheimer's disease (AD) is the most common form of dementia, accounting for 50-80 percent of cases globally. By 2050, there are estimated to be 131 million cases of Alzheimer's disease. There is presently no medication that can slow or stop the progression of the disease. Moreover, the late diagnosis of Alzheimer's disease is a significant impediment to effective disease management. However, some well-known and recently discovered AD biomarkers could be used to detect the illness early on and track its course. Because of their efficacy as diagnostic tools, proteins like NfL, MMPs, p-tau217, YKL-40, SNAP-25, VCAM-1, and Ng/BACE are among the most promising biomarkers. For instance, Recent research has revealed the predictive utility of plasma p-tau217 in distinguishing Alzheimer's disease from other neurodegenerative illnesses, particularly as an accurate predictor of -amyloidosis at both the asymptomatic and symptomatic stages.

Restraint:

With the high cost of the validation process, such as sample collection & storage, government rules and policies are changing since reimbursements do not cover biomarker-mediated therapies that are not considered standard of care. Even though biomarkers add significant value to tests, reimbursements are limited. For instance, Medicare, the nation's largest healthcare insurer with more than 50 million beneficiaries, does not fund experimental medicines or most screening and biomarker tests. Therefore, above are some of the factors that the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

Patients with COVID-19 typically report suffering neurological symptoms. Anosmia is a common CNS symptom induced by viral contact with neurons or supporting cells in the nasal olfactory tissues. The most common symptom of CNS dysfunction is diffuse encephalopathy, which is most likely caused by the CNS consequences of the systemic inflammatory state associated with severe COVID-19. Moreover, CSF and plasma biomarkers will very certainly play a vital role in the clinical evaluation of patients with neuro-COVID, both during the acute phase of infection and for managing long-term complications. Unnecessary deaths.

Also, in the early stages of the pandemic, the rate of patient screening and diagnosis is greatly hampered since governments worldwide instituted restrictions such as lockdowns to stop the disease from spreading. Screening, diagnosis and treatment delays would probably result in a short-term decrease in CNS diagnoses, followed by an increase in late-stage diagnoses and deaths due to limited healthcare coverage. As a result of the expanding number of COVID-19 cases, there is more evidence of CNS injury in COVID-19 patients utilizing serological biomarkers.

Segment Analysis

Safety Biomarker segment is expected to hold the largest market share in central nervous system (CNS) biomarkers market.

The safety biomarker segment accounted for the largest market share in 2020. Growing awareness about routine health checkups and rising use in the preclinical stage are some of the factors the segment is expected to boost in the forecast period. For instance, according to a report published by a coalition of pharmaceutical companies in December 2020, 83 percent of the 24 companies surveyed used safety biomarkers throughout the clinical trials phase. In addition, great effort is being made to qualify biomarkers to be employed in preclinical and clinical trials to speed up medication development.

Geographical Analysis

North America region holds the largest market share in the global central nervous system (CNS) biomarkers market

In 2020, North America accounted for the highest revenue share. The rising CNS cancer cases and increasing R&D expenditure are some of the factors which are expected to boost the market in the forecast period. For instance, According to the American Cancer Society, brain cancer will be the second most commonly diagnosed cancer in children and adolescents in 2021, with a proportion of 27 percent and 21 percent in children and adolescents, respectively, where CNS biomarkers are used.

Furthermore, businesses and research institutes continually innovate and develop new technologies and biomarkers, which significant players aid in the region. As per the American Cancer Society, as of August 2020, USD 23.1 million has been allocated to brain-related clinical and cancer control research in the United States. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the central nervous system (CNS) biomarkers market are Banyan Biomarkers Inc., Thermo Fisher Scientific Inc., Merck KGaA(Sigma Aldrich), G-Biosciences, Zeus Scientific , Roche, Abacus Diagnostica and SGS OFFICES & LABS. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which contribute to the global growth of the central nervous system (CNS) biomarkers market. For instance, Accure Therapeutics announced its launch in June 2020, with EUR 7.6 million in Series A investment. The pharmaceutical business established in Barcelona will focus on discovering therapy candidates for CNS illnesses such as Parkinson's disease.

Banyan Biomarkers, Inc.:

Overview:

Banyan Biomarkers, Inc., headquartered in Gainesville, Florida, was founded in 2002. The company's biomarkers aim to eliminate the need for CT scans in patients with a suspected mild traumatic brain injury based on actual data rather than subjective interpretation, allowing physicians to identify and triage patients who require additional medical attention while also reducing unnecessary CT scan radiation exposure.

Product Portfolio:

BANYAN BTI: The BANYAN BTI measures the levels of two proteins, Ubiquitin C-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP), released from the brain into the circulation and assessed within 12 hours of a head injury.

Why Purchase the Report?

  • Visualize the composition of the global central nervous system (CNS) biomarkers market segmentation by type, application, Disease, end user and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in global central nervous system (CNS) biomarkers market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of global central nervous system (CNS) biomarkers market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global central nervous system (CNS) biomarkers market report would provide an access to an approx.45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Central Nervous System (CNS) Biomarkers Market - By Type

  • Safety Biomarker
  • Efficacy Biomarker
  • Validation Biomarker
  • Others

Global Central Nervous System (CNS) Biomarkers Market - By Application

  • Drug Discovery & Development
  • Personalized Medicines
  • Disease Risk Assessment
  • Diagnostics
  • Others

Global Central Nervous System (CNS) Biomarkers Market - By Disease

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Traumatic Brain Injury
  • Others

Global Central Nervous System (CNS) Biomarkers Market - By End user

  • Diagnostic Labs
  • Clinics
  • Hospitals
  • Research Centers
  • Others

Global Central Nervous System (CNS) Biomarkers Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa
Product Code: DMBT4407

Table of Contents

1. Global Central Nervous System (CNS) Biomarkers Market - Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Central Nervous System (CNS) Biomarkers Market - Market Definition and Overview

3. Global Central Nervous System (CNS) Biomarkers Market - Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Application
  • 3.3. Market Snippet by Disease
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Region

4. Global Central Nervous System (CNS) Biomarkers Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The development of novel biomarkers for diagnosing and treating Alzheimer's disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost of the validation process, such as sample collection & storage, government rules and policies are changing since reimbursements do not cover biomarker-mediated therapies that are not considered standard of care.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Central Nervous System (CNS) Biomarkers Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Central Nervous System (CNS) Biomarkers Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion
  • 6.7. Others

7. Global Central Nervous System (CNS) Biomarkers Market - By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Safety Biomarker*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Efficacy Biomarker
  • 7.4. Validation Biomarker
  • 7.5. Others

8. Global Central Nervous System (CNS) Biomarkers Market - By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Drug Discovery & Development*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Personalized Medicines
  • 8.4. Disease Risk Assessment
  • 8.5. Diagnostics
  • 8.6. Others

9. Global Central Nervous System (CNS) Biomarkers Market - By Disease

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 9.1.2. Market Attractiveness Index, By Disease Segment
  • 9.2. Alzheimer's disease*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Multiple Sclerosis
  • 9.4. Parkinson's Disease
  • 9.5. Traumatic Brain Injury
  • 9.6. Others

10. Global Central Nervous System (CNS) Biomarkers Market - By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Diagnostic Labs*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 10.3. Clinics
  • 10.4. Hospitals
  • 10.5. Research Centers
  • 10.6. Others

11. Global Central Nervous System (CNS) Biomarkers Market - By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, US$ Million, 2019-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

12. Global Central Nervous System (CNS) Biomarkers Market - Competitive Landscape

  • 12.1. Key Developments and Strategies
  • 12.2. Company Share Analysis
  • 12.3. Product Benchmarking
  • 12.4. List of Key Companies to Watch
  • 12.5. List of Company with disruptive technology

13. Global Central Nervous System (CNS) Biomarkers Market- Company Profiles

  • 13.1. Banyan Biomarkers Inc.*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Key Highlights
    • 13.1.4. Financial Overview
  • 13.2. Thermo Fisher Scientific Inc.
  • 13.3. Merck KGaA(Sigma Aldrich)
  • 13.4. G-Biosciences
  • 13.5. Zeus Scientific
  • 13.6. Roche
  • 13.7. Abacus Diagnostica
  • 13.8. SGS OFFICES & LABS

LIST NOT EXHAUSTIVE

14. Global Central Nervous System (CNS) Biomarkers Market - DataM

  • 14.1. Appendix
  • 14.2. About Us
  • 14.3. Contact Us